Synthesis and Anti-Hepatitis B Virus and Anti-Hepatitis C Virus Activities of 7-Deazaneplanocin A Analogues in Vitro

• Published in: Journal of medicinal chemistry 2009-01, Vol.52 (1), p.206-213
• Main Authors: Kim, Hyo-Joong, Sharon, Ashoke, Bal, Chandralata, Wang, Jianing, Allu, Madhan, Huang, Zhuhui, Murray, Michael G, Bassit, Leda, Schinazi, Raymond F, Korba, Brent, Chu, Chung K
• Format: Article
• Language: English
• Subjects: Adenosine - analogs & derivatives; Adenosine - chemical synthesis; Adenosine - chemistry; Adenosine - pharmacology; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Antiviral Agents - chemical synthesis; Antiviral Agents - chemistry; Antiviral Agents - pharmacology; Biological and medical sciences; Cell Line, Tumor; Cell Survival - drug effects; Hepacivirus - drug effects; Hepacivirus - physiology; Hepatitis B virus - drug effects; Hepatitis B virus - genetics; Humans; Medical sciences; Molecular Structure; Mutation - genetics; Pharmacology. Drug treatments; Virus Replication - drug effects
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/jm801418v

A series of 7-deazaneplanocin A (7-DNPA, 2) analogues were synthesized and evaluated for in vitro antiviral activity against HBV and HCV. The syntheses of target carbocyclic nucleosides were accomplished via a convergent procedure. 7-Substitutions were introduced by using 7-substituted-7-deaza heterocyclic base precursors (F, Cl, Br, and I) or via substitution reactions after the synthesis of the carbocyclic nucleosides. Among the synthesized compounds, 2, 13−15, 24, and 27 exhibited significant anti-HCV activity (EC50 ranged from 1.8 to 20.1 μM) and compounds 2, 15, 22, and 24 demonstrated moderate to potent anti-HBV activity (EC50 = 0.3−3.3 μM). In addition, compound 24 also showed activity against lamivudine- and adefovir-associated HBV mutants.